Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS2319 in Healthy Subjects and Cancer Cachexia
NCT07735104Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of QLS2319 in cancer cachexia, sponsored by Qilu Pharmaceutical. Started Sep 2026; status: recruiting.
02
Drugs
QLS2319
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT07735104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735104.